Van Winden Kristi R, Quintero Rubén A, Kontopoulos Eftichia V, Korst Lisa M, Llanes Arlyn, Chmait Ramen H
a Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine , Keck School of Medicine, University of Southern California , Los Angeles , CA , USA and.
J Matern Fetal Neonatal Med. 2015 Sep;28(13):1549-53. doi: 10.3109/14767058.2014.960834. Epub 2014 Sep 29.
To evaluate the impact of selective intrauterine growth restriction (SIUGR) on monochorionic multiples treated with selective laser photocoagulation of communicating vessels (SLPCVs) for twin-twin transfusion syndrome (TTTS).
Perinatal survival was compared among TTTS patients with and without SIUGR. The TTTS + SIUGR group was defined as TTTS patients with donor twin weight <10th percentile. Multivariable logistic regression analyses identified factors associated with 30-day survival.
Of 369 patients, 65% (N = 241) had TTTS + SIUGR. Thirty-day donor twin survival for the TTTS-only group was 84% versus 75% in the TTTS + SIUGR group (p = 0.0348). Stage III donor involved (stage III donor, donor/recipient) TTTS + SIUGR patients (N = 110) had 66% 30-day donor survival. Multivariable logistic regression demonstrated that the TTTS-only group was twice as likely to achieve donor survival compared to the TTTS + SIUGR group (OR 2.01, 95% CI 1.11-3.66, p = 0.0214). In the TTTS + SIUGR group, patients not classified as stage III donor-involved were twice as likely to achieve donor survival as stage III donor-involved patients (OR 2.02, 95% CI 1.10-3.71, p = 0.0226).
SIUGR, present in two-thirds of TTTS patients, was a risk factor for decreased donor survival. Patients with donor SIUGR and umbilical artery persistent or reversed end-diastolic flow (Quintero Stage III Donor-involved) were especially at risk.
评估选择性宫内生长受限(SIUGR)对接受双胎输血综合征(TTTS)的单绒毛膜多胎妊娠行选择性激光凝固交通血管(SLPCV)治疗的影响。
比较有和没有SIUGR的TTTS患者的围产期生存率。TTTS + SIUGR组定义为供体双胎体重低于第10百分位数的TTTS患者。多变量逻辑回归分析确定与30天生存率相关的因素。
在369例患者中,65%(N = 241)患有TTTS + SIUGR。单纯TTTS组供体双胎30天生存率为84%,而TTTS + SIUGR组为75%(p = 0.0348)。涉及III期供体(III期供体、供体/受体)的TTTS + SIUGR患者(N = 110)30天供体生存率为66%。多变量逻辑回归表明,与TTTS + SIUGR组相比,单纯TTTS组实现供体生存的可能性是其两倍(OR 2.01,95%CI 1.11 - 3.66,p = 0.0214)。在TTTS + SIUGR组中,未分类为涉及III期供体的患者实现供体生存的可能性是涉及III期供体患者的两倍(OR 2.02,95%CI 1.10 - 3.71,p = 0.0226)。
SIUGR存在于三分之二的TTTS患者中,是供体生存降低的危险因素。患有供体SIUGR且脐动脉舒张末期血流持续或反向(昆特罗III期涉及供体)的患者尤其危险。